TrialThe Lancet. Oncology2012

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Nicholas D James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.